Quince Therapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $35.4M | $18.6M | $9.4M | $25.2M | $60.8M | $61.3M | $30.2M |
| SG&A Expense | — | $15.0M | $17.6M | $17.7M | $26.0M | $29.5M | $17.6M | $9.0M |
| Operating Income | — | $-58.1M | $-57.3M | $-34.6M | $-52.0M | $-90.3M | $-78.9M | $-39.2M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-80.8M | $-56.7M | $-31.6M | $-51.9M | $-89.9M | $-76.8M | $-37.0M |
| Income Tax Expense | — | $3.2M | $87.0K | $-197.0K | $-284.0K | $0 | $0 | $0 |
| Net Income | — | $-84.0M | $-56.8M | $-31.4M | $-51.7M | $-89.9M | $-76.8M | $-37.0M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 | $-2.63 | $-1.94 |
| EPS (Diluted) | — | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 | $-2.63 | $-1.94 |
| Shares Outstanding (Basic) | 163.0M | 50.1M | 43.3M | 37.2M | 33.5M | 29.7M | 29.5M | 26.9M |
| Shares Outstanding (Diluted) | 163.0M | 50.1M | 43.3M | 37.2M | 33.5M | 29.7M | 29.5M | 26.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |